In addition, there was some mention of possible licensing in the 28th April 2016 Shareholder Update;
"Meetings have taken place in New York with the Coty development group. Coty has informed OBJ that it is undertaking various pre-launch claims support using OBJ’s dermaportation device with new formulation chemistries. Using a more high-end complex device, the approach to market will require longer consumer input than the micro array approach of P&G, though it is expected that a determination will be forthcoming during early 2016.
The parties remain positive in moving the opportunity forward to first phase licensing, subject to completion of the present claims support work."
OBJ Price at posting:
7.0¢ Sentiment: Hold Disclosure: Held
(20min delay)